Thiol-Reactive ADC Linkers for Higher Payload, Lower Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges with narrow therapeutic windows and unpredictable dose-limiting toxicities due to their inability to discriminate between normal and malignant cells, leading to off-target toxicity and limited clinical efficacy.
Innovation Solution
Development of linkers with thiol-reactive groups, such as substituted acrylic and propiolic groups, to conjugate cytotoxic agents to cell-binding molecules, allowing for site-specific attachment and increased drug loading, thereby enhancing targeted delivery and minimizing off-target exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional chemotherapy is used, then broad coverage of malignant cells is achieved, but off-target toxicity to normal cells increases
Solution Approach 1:
The drug delivery system is segmented into distinct functional components: a cell-binding molecule (antibody) for target recognition, a linker for stable transport, and a cytotoxic payload for therapeutic action. This segmentation allows the cytotoxic drug to be delivered only to target cells while remaining inert during circulation, thereby maintaining broad coverage while reducing off-target toxicity.
Solution Approach 2:
The cell-binding molecule acts as an intermediary that selectively binds to antigens on malignant cells, mediating the delivery of the cytotoxic payload specifically to target cells. This intermediary mechanism ensures that the drug's broad coverage capability is maintained while its harmful effects are restricted to the intended target.
2Quantity of substance
If higher drug doses are administered to overcome narrow therapeutic window, then therapeutic efficacy improves, but dose-limiting toxicities increase
Solution Approach 1:
The patent converts the inherently toxic nature of cytotoxic drugs into a beneficial therapeutic effect by coupling the drug to a cell-binding molecule. The cytotoxic payload, which would normally cause harmful effects at therapeutic doses, is redirected to specifically kill malignant cells while sparing normal cells, thereby enabling higher effective doses without proportionally increasing harmful toxicities.
3Manufacturing precision
If site-specific conjugation is implemented, then batch-to-batch consistency improves, but manufacturing complexity increases
Solution Approach 1:
The conjugation process targets specific local sites on the cell-binding molecule, such as engineered cysteine residues or N-terminal amino groups, rather than random conjugation throughout the molecule. This local quality approach ensures consistent drug-to-antibody ratios and uniform product characteristics across batches, while the specificity of the target sites actually simplifies the manufacturing process by reducing the need for extensive purification to remove heterogeneous conjugates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed linkers enable prolonged circulation half-life, increased drug payload, and controlled drug ratios, resulting in improved therapeutic efficacy with reduced off-target toxicity and enhanced batch-to-batch consistency.
Implementation Method 1
linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, used for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule
Data Source
AI summary
The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.